Each of our four clinical-stage drug candidates target different mechanisms critical to overcoming cancer progression and drug resistance:

  • Pracinostat, an oral HDAC inhibitor;
  • ME-401, an oral PI3K delta inhibitor;
  • Voruciclib, an oral CDK inhibitor; and
  • ME-344, a mitochondrial inhibitor targeting the OXPHOS complex.
HDAC INHIBITOR Drug Candidate:

Pracinostat

INDICATION / COMBINATION

Acute Myeloid Leukemia

Unfit for intensive chemotherapy Vidaza® (Azacitidine)
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study
Phase 3 Pivotal Trial
INDICATION / COMBINATION

Myeloidyplastic Syndrome

High & Very High Risk Vidaza® (Azacitidine)
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study
P13K DELTA INHIBITOR Drug Candidate:

ME-401

INDICATION / COMBINATION

Follicular Lymphoma

Relapsed/Refractory Single agent
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study
Phase 2 Accelerated Approval Trial*
INDICATION / COMBINATION

B-Cell Malignancies

Relapsed/Refractory Single agent Rituxan® (rituximab) Zanubrutinib**
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study
Selective CDK Inhibitor Drug Candidate:

Voruciclib

INDICATION / COMBINATION

B-Cell Malignancies

Relapsed/Refractory Single agent
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study
Mitochondrial Inhibitor Drug Candidate:

ME-344

INDICATION / COMBINATION

HER2- Breast Cancer***

Treatment-na├»ve, early stage Avastin® (bevacizumab)
  • PRE-CLINICAL
  • CLINICAL PROOF OF CONCEPT
  • Marketing Approval Study

* Phase 2 study intended to support an accelerated approval marketing application with the FDA

** Study arm to be initiated under clinical collaboration with BeiGene, Ltd.

***Investigator-initiated study